24results about How to "Reduced expression level" patented technology

The invention discloses application of triflorin or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating heart aging and / or myocardial injury. The invention provides a new strategy and a candidate substance for developing medicines, health-care products or functional foods for preventing, delaying and / or treating heart aging and / or myocardial injury, maintaining heart health and reducing the risk of aging-related cardiovascular diseases.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

The invention relates to the technical field of biological medicine, and discloses a binding peptide targeting a C-terminal structural domain of human AARS1 protein and application, the binding peptide comprises an amino acid sequence represented by a general formula (I) and a Val-Ala-Xaa-Xaa-Arg-His core motif, and can specifically bind to the C-terminal structural domain of the human AARS1 protein. The binding peptide and the derivative thereof block an AARS1 mediated protein lactic acid modification signal channel by inhibiting the activity of AARS1 lactoacyltransferase or inducing protein degradation through a ubiquitin-proteasome pathway. The binding peptide provided by the invention avoids an N-terminal catalytic activity center of AARS1, does not influence the protein synthesis function of normal cells while exerting antitumor activity, has relatively high affinity and safety, and can be used for preparing drugs for treating AARS1 mediated diseases such as pancreatic cancer or a diagnostic reagent for detecting AARS1.

The invention relates to application of sulfated glycogen synthase kinase-3 in prevention and treatment of liver insulin resistance. Specifically, the invention provides an application of a hyposulfated GSK-3beta inhibitor in preparation of a medicine, and the medicine is used for preventing or treating insulin resistance; the invention further discloses application of the GSK-3beta knockout reagent in preparation of a medicine. The medicine is used for preventing or treating insulin resistance.

The application discloses a kind of substance for detecting tsRNA marker, including one or more of the following applications: A1) in the application in preparing diagnostic blood vessel senile product;A2) in the application in preparing screening blood vessel senile product;A3) in the application in preparing treatment blood vessel senile product;A4) in the application in preparing blood vessel senile prognosis evaluation product;A5) in the application in preparing product for distinguishing blood vessel senile and other diseases;tsRNA marker is tsRNA-3031b, nucleotide sequence is as shown in SEQ ID No.1.The tsRNA-3031b marker provided in the application is significantly increased in the expression amount in the plasma of blood vessel senile patient compared with healthy control, indicating that tsRNA-3031b is a potential blood vessel senile biomarker.The ROC curve of the efficiency in diagnosing blood vessel senile patient shows that tsRNA-3031b has good diagnostic efficiency.

The invention discloses a method for regulating and controlling pathological heart remodeling of an AAC model mouse by succinic acid, and belongs to the field of heart disease treatment. The method comprises the following steps: selecting 8-week-old male C57BL / 6J mice, dividing the mice into a normal temperature group and a slight cold exposure group, and carrying out adaptive feeding; establishing a heart remodeling model through an AAC operation; performing 1.5% succinic acid aqueous solution and / or 1mg / mL broad-spectrum antibiotic intervention on the mouse for 4 weeks; the method comprises the following steps: collecting heart tissues, detecting heart remodeling related indexes through Masson staining, WGA staining, qPCR, Western blot and other methods, and evaluating an intervention effect. According to the invention, succinic acid is used for intervention in a slightly cold exposure environment, so that AAC model mouse pathological heart remodeling is effectively regulated and controlled, and a new method and thought are provided for research and treatment of heart remodeling diseases.

The application discloses application of a PI3K-gamma-delta signal path inhibitor in preparation of a product for treating central nervous system leukemia and the product, and solves the technical problem that the prior art lacks a molecular targeting product for acute lymphoblastic leukemia with CNSL which has better effect. The application comprises: application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for treating acute lymphoblastic leukemia with central nervous system leukemia, and application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for inhibiting proliferation, invasion and migration of acute lymphoblastic leukemia with central nervous system leukemia. The application also comprises a product of the PI3K-gamma-delta signal path inhibitor. The application discloses that central nervous system leukemia is closely related to an expression level of MSLN, and the PI3K-gamma-delta signal path inhibitor can inhibit the infiltration degree of acute lymphoblastic leukemia with central nervous system leukemia by reducing the expression level of MSLN, and prolong the survival time.

The invention relates to the technical field of biological tissue engineering, in particular to a young mesenchymal stem cell-derived apoptotic body as well as a preparation method and application thereof. The apoptotic body is formed by inducing apoptosis of young mesenchymal stem cells through staurosporine. The apoptotic body can reduce the expression level of senescence-related factors and promote expression of matrix synthesis-related factors, so that a degeneration microenvironment is improved, extracellular matrix synthesis is promoted, and cell functions are improved. The apoptotic body can be applied to the field of delaying and reversing intervertebral disc degeneration, promotes repair and regeneration of intervertebral disc tissues by delivering rejuvenation signals, provides a new cell-free treatment strategy for treatment of intervertebral disc degeneration, avoids the risks of low cell survival rate, immunological rejection, tumorigenicity and the like, and has a good application prospect. Meanwhile, the traditional limitation of recovering tissue functions through physical or medicine means is broken through.

This invention provides the application of a uterine-derived Sphingomonas DS-28 strain and its metabolites in the treatment of endometritis, relating to the field of microbial technology. The Sphingomonas DS-28 strain provided by this invention possesses uterine colonization ability, good niche adaptability, and significant efficacy in treating Escherichia coli-induced endometritis. Animal experiments show that the preparation of this strain can effectively alleviate uterine redness and swelling, reduce pathological damage, and significantly reduce [the condition / progression]. TNF-alpha , IL-6 , IL-8 It inhibits gene expression and suppresses the NF-κB signaling pathway, exhibiting superior anti-inflammatory and tissue repair effects compared to other Sphingomonas strains C3-25.1, C3-41.1, and C3-42.1. Furthermore, the metabiotic preparation of this strain can also alleviate Escherichia coli-induced endometritis in mice, improve uterine redness and swelling, and reduce pathological damage.

The application discloses a kind of detection piRNA marker material, including one or more of the following applications: A1) in the application in the preparation of diagnostic blood vessel senile product;A2) in the application in the preparation of screening blood vessel senile product;A3) in the application in the preparation of evaluating blood vessel senile risk product;A4) in the application in the preparation of blood vessel senile prognosis evaluation product;A5) in the application in the preparation of distinguishing blood vessel senile and other diseases product;PiRNA marker is hsa_piR_017724, nucleotide sequence is as shown in SEQ ID No.1.The hsa_piR_017724 marker provided by the application is significantly increased in the expression amount in the plasma of blood vessel senile patient compared with healthy control, indicating that hsa_piR_017724 is a potential blood vessel senile biomarker.The ROC curve of the efficiency in diagnosing blood vessel senile patient shows that hsa_piR_017724 has good diagnostic efficiency.

The invention relates to an anti-dengue virus medicine containing a ferroptosis inhibitor and application of the anti-dengue virus medicine, in particular to medical application of the ferroptosis inhibitor in resisting dengue virus infection. In-vitro experiments prove that DENV infection can activate a host cell ferroptosis pathway; after 1-3 [mu] M of Ferrostatin-1 or Liproxstatin-1 is adopted for intervention, the activation of the pathway can be effectively inhibited, and the virus RNA replication and protein expression level can be remarkably reduced. According to the technical scheme, the existing activity of the known ferroptosis inhibitor is utilized, new indications for resisting DENV infection of the ferroptosis inhibitor are developed, a candidate drug strategy of a targeted ferroptosis pathway is provided for dengue treatment, the technical problem that the action target of an existing antiviral drug is limited is solved, and the obvious clinical application and development value is achieved.

The application discloses application of a pilose antler polysaccharide in preparation of a radioactive liver injury protection product and belongs to the technical field of biological pharmacy. The application of the pilose antler polysaccharide in preparation of the radioactive liver injury protection product shows that the polysaccharide can not only effectively reduce oxidative stress and inflammatory injury, but also specifically intervene in the core pathological mechanism of the radioactive liver injury, that is, the pilose antler polysaccharide can inhibit progressive liver fibrosis by down-regulating the expression of a TGF-beta signal path and regulate the expression balance of BAX / Bcl-2 genes to block liver cell apoptosis mediated by a mitochondrion path, thereby effectively relieving liver injury caused by ionizing radiation, and the pilose antler polysaccharide has no toxic side effects and has a wide application prospect.

This application discloses the use of Qi Xue Kang oral liquid in the preparation of drugs for the prevention or treatment of myocardial ischemia-reperfusion injury. The first aspect of this application discloses the use of Qi Xue Kang oral liquid in the preparation of drugs for the prevention or treatment of myocardial ischemia-reperfusion injury. Experiments have shown that its application in treating myocardial ischemia-reperfusion injury has better therapeutic effects compared to drugs such as Qi Shen Yi Qi Dripping Pills, significantly reducing the expression levels of myocardial injury markers, showing more pronounced pathological changes in myocardial tissue, and significantly improving the number of cardiomyocyte apoptosis.

The application relates to the field of biotechnology, and particularly relates to a lung adenocarcinoma diagnosis biomarker based on m 6 A lung adenocarcinoma diagnosis biomarker based on methylation modification of circular RNA and application thereof 6 A lung adenocarcinoma diagnosis biomarker based on methylation modification of circular RNA and application thereof 6 A lung adenocarcinoma diagnosis biomarker based on methylation modification of circular RNA and application thereof 6 A lung adenocarcinoma diagnosis biomarker based on methylation modification of circular RNA and application thereof The hsa_circ_0079039 modified by methylation can be used as a biomarker for diagnosing lung adenocarcinoma. The application has important value for screening and early diagnosis of lung adenocarcinoma.

The invention belongs to the technical field of biological medicines, and discloses application of tetrandrine in preparation of a medicine for inhibiting human papilloma virus infection. The invention discloses an application of tetrandrine or a pharmaceutically acceptable salt thereof in preparation of an anti-HPV (human papillomavirus) infection medicine. The application of the traditional Chinese medicine monomer component tetrandrine or the pharmaceutically acceptable salt thereof in preparation of the anti-HPV (especially high-risk HPV16) infection medicine is found and verified for the first time, the inhibition effect of the tetrandrine or the pharmaceutically acceptable salt thereof has the characteristic of concentration dependence, and a brand new technical path is opened up for research and development of the anti-HPV medicine.

This invention belongs to the field of genetic engineering technology and discloses a shRNA that targets and knocks down the HDAC5 gene. The sense strand of the shRNA is shown in SEQ ID NO.4, and the antisense strand is shown in SEQ ID NO.5. The sense and antisense strands anneal to form a double-stranded DNA with sticky ends. This invention utilizes lentivirus-mediated RNA interference technology to obtain a Vero cell line with stable HDAC5 gene knockdown, demonstrating that HDAC5 gene knockdown can inhibit PPRV proliferation, providing a novel potential target for the development of anti-PPRV drugs.

The present application relates to the field of molecular biology, and particularly relates to application of a reagent for regulating NDRG2 expression level in preparation of a preparation for treating preeclampsia. 6 A methylation modification level; and reducing the expression level of NDRG2. 6 A methylation modification regulates NDRG2 mRNA stability and further promotes the molecular mechanism of NDRG2 expression. 6 A methylation modification regulates NDRG2 mRNA stability and further promotes the molecular mechanism of NDRG2 expression. Based on this mechanism, by regulating the expression level of NDRG2, the present application effectively inhibits the invasion, migration and proliferation of placental trophoblast cells, promotes the expression of apoptosis and inflammatory factors, which provides a new technical means for targeted treatment of preeclampsia.

The application relates to an application of a traditional Chinese medicine composition in a drug for chronic obstructive pulmonary disease, characterized in that the traditional Chinese medicine composition comprises the following components in parts: Magnolia officinalis 1-100 parts, Strychnos ignatii 1-100 parts, Toddalia asiatica 1-100 parts, Ephedra 1-100 parts, Amygdalus 1-100 parts, Notopterygium 1-100 parts, Zingiber officinale 1-100 parts, Pogostemonis 1-100 parts, Perilla 1-100 parts, Atractylodes 1-100 parts, Poria cocos 1-160 parts, Atractylodes macrocephala 1-120 parts, Gypsum fibrosum 1-100 parts, Fructus Crataegi 1-100 parts, Fructus Junci 1-100 parts, Fructus Hordei 1-100 parts, Lumbricus 1-100 parts, Radix et Rhizoma Veratri 1-100 parts, Herba Eupatorii Fortunei 1-100 parts, Semen Lepidii 1-100 parts and Semen Platycladi 1-100 parts.

The application relates to the field of biological medicine, and particularly relates to a WDR6 gene and application thereof Wdr6 in preparation of a liver aging delaying product. Wdr6 Low expression can aggravate the liver aging degree, and liver-specific Wdr6 Overexpression can significantly down-regulate the expression of a p21 protein, which is a marker of aging, in liver tissues of naturally aging mice, and the number of cells that are positively colored by aging-related beta-galactosidase staining is significantly reduced, indicating that Wdr6 Overexpression can effectively maintain liver young homeostasis and delay liver aging. Meanwhile, through an in-vitro culture of a liver cell line aging model induced by bleomycin, it is verified that the WDR6 protein can increase the expression of a long-life protein SIRT1 protein, down-regulate the expression of a p21 protein, and reduce beta-galactosidase, so as to realize liver aging delay.

The invention discloses application of polynucleotide. It is found that when the polynucleotide sequence shown in SEQ ID NO: 5 is applied to somatic cells of naturally aged subjects in vitro, expression of senescence markers, DNA damage markers and premature protein in the somatic cells can be remarkably reduced, and the polynucleotide sequence has the potential curative effect of preventing or delaying senescence.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating gastric cancer and a preparation method thereof. The pharmaceutical composition for treating the gastric cancer is prepared from the following components: chelidonine and helicid, the mass ratio of the chelidonine to the helicid is 1: (1.5-2.5). According to the pharmaceutical composition, chelidonine and helicid are combined in a specific proportion for use and can synergistically inhibit the growth of gastric cancer transplanted tumors, the in-vivo tumor inhibition rate reaches 56.99%, and excellent anti-tumor activity and good clinical application prospects are shown.

The application discloses a culture medium for CAR-T cell culture and application thereof, and relates to the fields of immunology, molecular biology and cell engineering. The culture medium comprises a basic culture medium and dihydroeugenol. It is found in research that by adding dihydroeugenol in the culture medium, the proportion of central memory T cells of CAR-T cells can be effectively improved, and the expression levels of PD1 and LAG3 can be reduced. In addition, dihydroeugenol can also promote the secretion of IL2, TNF and INFgamma, and enhance the killing function of CAR-T cells. Experiments show that the ability of D-CAR-T to secrete IL2, TNF and INFgamma is significantly higher than that of ordinary CAR-T, and D-CAR-T also has a higher T CM cell proportion and a lower exhaustion level after performing the killing function.

The application relates to the field of tumor treatment drugs and discloses application of P5A ATPase as a target in preparation of a neuroblastoma treatment drug. It is found for the first time that P5A ATPase can affect the expression level of LRP8 protein and endoplasmic reticulum translocation of LRP8 signal peptide guided peptide chains, and further affect the growth and proliferation of neuroblastoma cells, so that a new target is provided for development of a neuroblastoma treatment drug. In addition, it is found that two P5A ATPase inhibitors, sodium metavanadate and DCC, can inhibit the endoplasmic reticulum translocation of LRP8 signal peptide guided peptide chains, reduce the expression level of LRP8 protein, and further inhibit the growth and proliferation of neuroblastoma cells, so that a new treatment drug for neuroblastoma is provided.

The invention discloses an application of subprostrate alkali in preparation of a melanoma immunotherapy drug, and relates to the technical field of medicines, and the subprostrate alkali is used for immunotherapy of melanoma by down-regulating the PD-1 protein level in T cells. Downregulation of the PD-1 protein level in T cells is realized by promoting ubiquitination of PD-1 through subprostrate alkali and inducing degradation of PD-1 through an endosome-lysosome way; the subprostrate alkali inhibits growth of melanoma by enhancing immune killing ability of T cells on melanoma cells and promoting immune infiltration of the T cells, can effectively promote ubiquitination modification of PD-1 protein in the T cells and induce degradation of the PD-1 protein in an endosome-lysosome way, so that the protein expression level of PD-1 is remarkably reduced, and the subprostrate alkali can be used for preparing a medicine for treating melanoma. The action does not depend on gene transcriptional regulation, the subprostrate alkali can obviously enhance the immune killing ability of the T cells to melanoma cells, and the survival rate of the tumor cells is obviously reduced in a co-culture system.